Abstract：
Although it has a poor prognosis, patients with lung adenocarcinoma (LUAD) have a relatively higher 5-year survival period. Thus, it is necessary to identify effective prognostic markers to evaluate the effect of early treatment. RS1 gene encodes retinoschisin, a key protein in congenital retinoschisis, while few studies have been reported on the association between RS1 and cancer prognosis.
We performed bioinformatic analyses based on the data obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases to demonstrate the expression level of RS1 was related to the LUAD prognosis and our findings were verified in-vitro and clinical samples. Then, we explored the potential mechanism of how RS1 expression influenced the prognosis of LUAD.
Compared with normal tissues, the RS1 expression was significantly lower in tumor tissues. The Multivariate Cox regression model showed that RS1 could be used as an independent prognostic indicator. Furthermore, we found significant differences in immune cell infiltration between RS1 high and low expression groups, and the proteasome pathway was found enriched in RS1 low expression samples.
In conclusion, our study suggests that RS1 is a novel prognostic biomarker for LUAD. Differences in immune cell infiltration and signaling pathways may contribute to the poor prognosis of LUAD caused by low RS1 expression.
We performed bioinformatic analyses based on the data obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases to demonstrate the expression level of RS1 was related to the LUAD prognosis and our findings were verified in-vitro and clinical samples. Then, we explored the potential mechanism of how RS1 expression influenced the prognosis of LUAD.
Compared with normal tissues, the RS1 expression was significantly lower in tumor tissues. The Multivariate Cox regression model showed that RS1 could be used as an independent prognostic indicator. Furthermore, we found significant differences in immune cell infiltration between RS1 high and low expression groups, and the proteasome pathway was found enriched in RS1 low expression samples.
In conclusion, our study suggests that RS1 is a novel prognostic biomarker for LUAD. Differences in immune cell infiltration and signaling pathways may contribute to the poor prognosis of LUAD caused by low RS1 expression.
摘要：
虽然预后较差,肺腺癌(LUAD)患者的5年生存期相对较高.因此，有必要确定有效的预后指标来评估早期治疗的效果。RS1基因编码视网膜裂素，先天性视网膜裂孔的关键蛋白，虽然很少有研究报道RS1与癌症预后之间的关系。
我们基于从癌症基因组图谱和基因表达综合数据库获得的数据进行了生物信息学分析，以证明RS1的表达水平与LUAD预后相关，并且我们的发现已在体外和临床样本中得到验证。然后，我们探讨了RS1表达影响LUAD预后的潜在机制。
与正常组织相比，RS1在肿瘤组织中的表达显著降低。多因素Cox回归模型显示RS1可作为独立的预后指标。此外，我们发现RS1高表达组和低表达组之间的免疫细胞浸润存在显着差异，在RS1低表达样品中发现了蛋白酶体途径的富集。
总之,我们的研究提示RS1是LUAD的一个新的预后生物标志物.免疫细胞浸润和信号通路的差异可能导致低RS1表达导致的LUAD预后不良。
我们基于从癌症基因组图谱和基因表达综合数据库获得的数据进行了生物信息学分析，以证明RS1的表达水平与LUAD预后相关，并且我们的发现已在体外和临床样本中得到验证。然后，我们探讨了RS1表达影响LUAD预后的潜在机制。
与正常组织相比，RS1在肿瘤组织中的表达显著降低。多因素Cox回归模型显示RS1可作为独立的预后指标。此外，我们发现RS1高表达组和低表达组之间的免疫细胞浸润存在显着差异，在RS1低表达样品中发现了蛋白酶体途径的富集。
总之,我们的研究提示RS1是LUAD的一个新的预后生物标志物.免疫细胞浸润和信号通路的差异可能导致低RS1表达导致的LUAD预后不良。
